Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation

J Infect Dis. 2011 Oct 1;204(7):1046-53. doi: 10.1093/infdis/jir466.

Abstract

Background: Herd immunity is important in the effectiveness of conjugate polysaccharide vaccines against encapsulated bacteria. A large multicenter study investigated the effect of meningococcal serogroup C conjugate vaccine introduction on the meningococcal population.

Methods: Carried meningococci in individuals aged 15-19 years attending education establishments were investigated before and for 2 years after vaccine introduction. Isolates were characterized by multilocus sequence typing, serogroup, and capsular region genotype and changes in phenotypes and genotypes assessed.

Results: A total of 8462 meningococci were isolated from 47 765 participants (17.7%). Serogroup prevalence was similar over the 3 years, except for decreases of 80% for serogroup C and 40% for serogroup 29E. Clonal complexes were associated with particular serogroups and their relative proportions fluctuated, with 12 statistically significant changes (6 up, 6 down). The reduction of ST-11 complex serogroup C meningococci was probably due to vaccine introduction. Reasons for a decrease in serogroup 29E ST-254 meningococci (from 1.8% to 0.7%) and an increase in serogroup B ST-213 complex meningococci (from 6.7% to 10.6%) were less clear.

Conclusions: Natural fluctuations in carried meningococcal genotypes and phenotypes a can be affected by the use of conjugate vaccines, and not all of these changes are anticipatable in advance of vaccine introduction.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bacterial Capsules / genetics
  • Bacterial Capsules / metabolism
  • Carrier State / immunology
  • Genotype
  • Humans
  • Immunity, Herd / immunology*
  • Mass Vaccination
  • Meningitis, Meningococcal / genetics
  • Meningitis, Meningococcal / immunology
  • Meningitis, Meningococcal / prevention & control*
  • Meningococcal Vaccines / administration & dosage*
  • Multilocus Sequence Typing
  • N-Acetylneuraminic Acid / genetics*
  • N-Acetylneuraminic Acid / metabolism
  • Neisseria meningitidis / genetics*
  • Neisseria meningitidis / immunology*
  • Serotyping
  • United Kingdom
  • Young Adult

Substances

  • Meningococcal Vaccines
  • serogroup C meningococcal conjugate vaccine
  • N-Acetylneuraminic Acid